{
  "pmcid": "11056492",
  "sha256": "44c71e22ee0506ac65e43da52348169ecea8373ee66ee086d9969883a9a939b2",
  "timestamp_utc": "2025-11-09T23:11:59.395144+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.971308520599251,
    "reading_ease": 31.787075140449446,
    "word_count": 267
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Bilateral Remote Ischemic Conditioning in Children: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This double-blind, randomised controlled trial was conducted at Birmingham and Leeds Children's Hospitals, UK. A total of 120 children aged 3 to 36 months were randomised 1:1 to receive RIPC or a sham procedure."
      },
      "Participants": {
        "score": 2,
        "evidence": "120 children aged 3 to 36 months were randomised 1:1 to receive RIPC or a sham procedure."
      },
      "Intervention": {
        "score": 2,
        "evidence": "120 children aged 3 to 36 months were randomised 1:1 to receive RIPC or a sham procedure."
      },
      "Objective": {
        "score": 1,
        "evidence": "The objective was to assess whether bilateral remote ischemic preconditioning (RIPC) offers cardioprotection in children undergoing surgery for tetralogy of Fallot (TOF) or ventricular septal defect (VSD)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the area under the curve (AUC) for high-sensitivity troponin-T in the first 24 hours post-surgery, analysed by intention-to-treat."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a secure online system with allocation concealment, and blinding was maintained for patients, clinicians, and outcome assessors."
      },
      "Blinding": {
        "score": 3,
        "evidence": "blinding was maintained for patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between October 2016 and December 2020, 120 children were randomised: 60 to RIPC and 60 to control."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The primary outcome showed a higher AUC for troponin-T in the RIPC group (mean: 70.0 ± 50.9 μg/L/h) compared to controls (mean: 55.6 ± 30.1 μg/L/h) with a mean difference of 13.2 μg/L/h (95% CI, 0.5-25.8; P = .04)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The primary outcome showed a higher AUC for troponin-T in the RIPC group (mean: 70.0 ± 50.9 μg/L/h) compared to controls (mean: 55.6 ± 30.1 μg/L/h) with a mean difference of 13.2 μg/L/h (95% CI, 0.5-25.8; P = .04)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar, with 4 serious events in the RIPC group and 5 in controls, none related to the intervention."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ISRCTN12923441"
      },
      "Funding": {
        "score": 0,
        "evidence": "The trial was funded by [source not specified]."
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}